查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990146

黏液囊炎治疗市场：依治疗方法、产品类型、应用部位及最终用户划分－2026-2032年全球市场预测

Bursitis Treatment Market by Treatment Type, Product Category, Application Site, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，黏液囊炎治疗市场价值将达到 15.9 亿美元，到 2026 年将成长至 17.3 亿美元，到 2032 年将达到 31.5 亿美元，复合年增长率为 10.23%。

主要市场统计数据
基准年 2025 15.9亿美元
预计年份：2026年 17.3亿美元
预测年份：2032年 31.5亿美元
复合年增长率 (%) 10.23%

简要介绍黏液囊炎的治疗途径、患者负担、多学科护理以及影响现代临床实践的系统因素。

黏液囊炎是一种常见但常被低估的疼痛和功能障碍原因，影响着不同族群。临床上，其症状从急性发炎发作到慢性疾病不等，慢性疾病会限制活动，干扰工作和休閒。治疗策略包括保守的自我护理、药物治疗、影像导引註射、復健治疗，以及在某些情况下进行手术介入。人口老化、耐力运动和高强度运动参与度的提高，以及代谢性疾病和风湿性疾病合併症的高发生率等人口结构变化，使得疾病的治疗路径日益复杂。

变革性的临床技术和供应趋势正在重新定义黏液囊炎治疗决策、护理服务模式和相关人员。

近年来，黏液囊炎的治疗格局发生了重大变革，这主要得益于临床创新、医疗服务水准的提高以及相关人员期望的转变。再生医学和生物目标疗法的进步为传统的皮质类固醇疗法提供了替代方案，而成像技术和超音波引导技术的改进则提高了注射疗法的精准性和安全性。同时，微创手术技术，特别是关节镜手术，明确了手术治疗的适应症，并缩短了合适患者的復原时间。

美国近期采取的关税措施如何从采购、价格压力、供应弹性和治疗可用性等方面重塑整个黏液囊炎治疗过程？

美国近期关税调整对医疗用品和药品整个价值链产生了连锁反应，累积效应影响着治疗方案的可近性、采购方式和成本结构。进口医疗设备、注射剂和生技药品的关税上涨增加了部分产品的接收成本，促使供应链相关人员重新评估其筹资策略。因此，一些製造商和经销商正在加速供应商网路多元化，探索关键零件的近岸外包和回流生产，并协商替代贸易条款，以维持利润率并确保向医疗机构稳定供应。

深入了解治疗方法、产品分类、解剖适应症和临床环境，将有助于阐明实施模式和临床工作流程。

详细的细分方法揭示了治疗方法应用方式、最积极参与的相关人员以及创新集中的领域等方面的关键细微差别。从治疗方式的角度观点，治疗方法范围涵盖了从居家照护（例如冰敷、休息/制动和热敷）到药物治疗（包括非处方和处方非类固醇消炎剂），甚至注射疗法（其中皮质类固醇注射仍然占主导地位，但也包括透明质酸和富血小板血浆疗法等较新的选择）。物理治疗包括冷疗、运动疗法和手法治疗，而外科手术通常分为关节镜和开放性手术。在每个细分领域中都可以观察到明显的趋势。在初期阶段，由于优先考虑可及性和低成本，通常会采用保守的居家照护和口服药物。然而，如果症状持续存在或需要更积极的治疗才能达到功能目标，通常会采用注射疗法或手术介入。

主要全球市场临床实践模式、报销方式、监管管道和供应链因素的关键区域差异影响着临床引入。

区域趋势对黏液囊炎的诊断、治疗和报销有显着影响，各大区域呈现明显的模式。在美洲，医疗服务倾向于优先考虑快速获得介入治疗和完善的门诊管道。私人保险公司的组成以及门诊手术中心的扩张影响注射疗法和关节镜手术的分布。在欧洲、中东和非洲，由于报销系统、管理体制以及先进生技药品取得途径的差异，医疗保健的差异性增加。在许多市场，集中采购和统一的国家指南影响着高成本治疗的推广，而公共医疗体系在製定标准治疗方案方面发挥着至关重要的作用。在亚太地区，一些国家人口老化迅速，其他国家体育运动参与率高，这些人口趋势推动了对保守治疗和介入治疗的需求。同时，製造地和区域供应链影响产品的供应和价格趋势。

对竞争对手、策略伙伴关係关係和实证差异化在塑造黏液囊炎治疗和服务商业性格局中的作用进行洞察和分析。

黏液囊炎治疗领域的竞争格局呈现出多元化的格局，参与者包括成熟的製药公司、医疗设备製造商、生技药品和再生医学专业开发商、数位医疗供应商以及支持分销和临床培训的服务供应商。参与企业企业继续利用其规模、临床资源和丰富的产品系列，确保在医院和门诊中心获得充足的市场份额。同时，小规模的专业公司则专注于利基创新，特别是再生医学注射、照护现场生技药品处理和新型给药系统。此外，数位疗法和远距復健供应商也日益受到重视，他们能够帮助患者长期坚持运动疗法，并促进远距临床医生的指导。

製造商、医疗保健提供者和支付方采用的实用、循证的策略建议，旨在提高临床价值、供应弹性和以患者为中心的结果。

产业领导者和临床专案经理应采取多管齐下的策略，以创造临床价值、改善患者疗效并降低商业性风险。首先，必须优先为新型注射剂和再生医学方案建立高品质的实证医学证据。将随机对照试验与可操作的真实世界研究相结合，将有助于与支付方合作并推动相关研究成果被纳入指南。其次，供应链多元化并考虑关键部件的近岸外包，将有助于降低关税波动和运输中断带来的风险；同时，与集团采购商签订战略合同，将有助于稳定价格和供应。第三，投资临床医生教育以及超音波引导注射和微创手术的系统化实施项目，将有助于规范操作并降低治疗结果的差异性。

为了确保获得可靠的见解，我们采用了严谨的混合调查方法，结合了专家访谈、临床文献整合、供应链分析和使用资料检验。

这些研究结果是基于多层次的调查方法，旨在从临床实践模式、采购行为和创新趋势三个方面进行三角验证。主要研究内容包括对骨科医生、物理治疗师、介入性疼痛专家、门诊手术经理和保险公司医疗保健主管进行结构化访谈，以了解他们对治疗方法选择、实施障碍和营运限制的实际观点。次要分析则利用同侪审查的临床文献、专业学会指南和监管文件，评估药物治疗、注射治疗、復健和手术方法的比较证据依证。供应链图谱和贸易数据分析揭示了采购方面的薄弱环节以及关税波动对零件供应的潜在影响。

结论强调，临床创新、医疗服务转型、保险公司的压力以及供应韧性相互交织，共同塑造黏液囊炎治疗的未来。

总之，多种因素正在重塑黏液囊炎的治疗格局：生技药品和影像引导介入治疗方法的创新、远端医疗和居家医疗能力的提升、健康保险公司对疗效和成本效益的日益重视，以及影响产品供应和定价的供应链压力。这些趋势为临床和商业领域的相关人员带来了挑战和机会。临床医生需要在遵循实证实践流程的同时整合新的治疗方法，製造商需要展现明显的比较优势，而医疗保健系统则需要製定稳健的筹资策略，以确保患者能够获得完整的、持续的治疗。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：黏液囊炎治疗市场：依治疗类型划分

  • 居家照护
    • 冰敷疗法
    • 休息/固定
    • 热敷
  • 注射疗法
    • 肾上腺皮质激素注射
    • 玻尿酸注射
    • 富血小板血浆疗法
  • 口服药物
    • 非处方非类固醇消炎剂
    • 非类固醇消炎剂（NSAIDs）
  • 物理治疗
    • 冷冻疗法
    • 运动疗法
    • 手法治疗
  • 手术治疗
    • 关节镜手术
    • 开放性手术

第九章：黏液囊炎治疗市场：依产品类型

  • 抗生素
  • 生技药品
  • 皮质类固醇
  • 非类固醇消炎剂

第十章：黏液囊炎治疗市场：依应用部位划分

  • 弯头
  • 脚跟
  • 髋关节
  • 膝盖
  • 肩膀

第十一章：黏液囊炎治疗市场：依最终用户划分

  • 门诊手术中心
  • 居家照护设施
  • 医院
  • 整形外科诊所
  • 运动医学中心

第十二章：黏液囊炎治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：黏液囊炎治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：黏液囊炎治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国黏液囊炎治疗市场

第十六章：中国黏液囊炎治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Arinna Lifesciences Ltd.
  • AstraZeneca PLC
  • Bioanalytical Systems, Inc.
  • Bristol-Myers Squibb Company
  • Crescent Formulations Pvt.Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Topcon Corporation
Product Code: MRR-5D693B46C73C

The Bursitis Treatment Market was valued at USD 1.59 billion in 2025 and is projected to grow to USD 1.73 billion in 2026, with a CAGR of 10.23%, reaching USD 3.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.59 billion
Estimated Year [2026] USD 1.73 billion
Forecast Year [2032] USD 3.15 billion
CAGR (%) 10.23%

A concise introduction to bursitis treatment pathways, patient burden, multidisciplinary care, and the systemic forces shaping contemporary clinical practice

Bursitis represents a common yet often underestimated source of pain and functional limitation across diverse patient populations. In clinical practice, presentations range from acute inflammatory flares to chronic, activity-limiting conditions that impair work performance and recreational participation. Management strategies span conservative self-care measures, pharmacologic treatment, image-guided injections, rehabilitative interventions, and, in select cases, surgical procedures. Demographic shifts such as population aging, rising participation in endurance and high-impact sports, and persistent rates of comorbid metabolic and rheumatologic conditions have collectively increased the complexity of care pathways for this condition.

In addition, evolving expectations around rapid recovery, minimally invasive approaches, and minimized opioid exposure shape both clinician decision-making and payer scrutiny. Care delivery has also been altered by expanded remote care modalities; patients increasingly seek timely advice and guided rehabilitation that reduce the need for in-person visits. Moreover, the growing emphasis on outcomes, functional restoration, and cost-effective care has prompted multidisciplinary collaboration among primary care physicians, orthopedic specialists, physiotherapists, and pain management teams. This introduction sets the stage for a deeper examination of market dynamics, treatment innovations, reimbursement influences, and operational pressures that together define the contemporary landscape of bursitis treatment.

Transformative clinical, technological, and supply dynamics that are redefining treatment decisions, care delivery models, and stakeholder incentives in bursitis management

Over the last several years, the treatment landscape for bursitis has undergone substantive transformation driven by clinical innovation, care delivery evolution, and shifting stakeholder expectations. Advances in regenerative medicine and targeted biologic therapies have introduced alternatives to traditional corticosteroid approaches, while improved imaging techniques and ultrasound guidance have increased the precision and safety of injectable interventions. Concurrently, minimally invasive surgical techniques, particularly arthroscopic methods, have refined indications for operative management and reduced convalescence times for appropriate candidates.

Complementing therapeutic innovation, digital health enablers such as tele-rehabilitation platforms, remote monitoring, and patient-facing education tools have extended the reach of physical therapy and self-management programs. These tools are increasingly integrated into care pathways to support adherence to exercise therapy, facilitate clinician oversight, and provide real-time feedback on recovery trajectories. On the payer and provider sides, value-based contracting and outcome-focused procurement pressures are incentivizing evidence generation and cost-effectiveness studies, which in turn shape adoption patterns. Finally, supply chain volatility and an increased emphasis on domestic resilience are causing manufacturers and health systems to reassess sourcing strategies for implants, injectables, and home-care devices. Taken together, these shifts are moving the field toward more personalized, data-driven, and care-continuum-oriented approaches that prioritize measurable functional outcomes and patient experience.

How recent United States tariff measures are reshaping procurement, pricing pressures, supply resilience, and therapeutic availability across bursitis care pathways

Recent tariff changes in the United States have reverberated through the medical supply and pharmaceutical value chains, producing cumulative effects that influence treatment availability, procurement practices, and cost structures. Tariffs that affect imported medical devices, injectables, and biologic inputs increase the landed cost of certain products, prompting supply chain actors to reassess sourcing strategies. Consequently, some manufacturers and distributors have accelerated diversification of supplier networks, considered nearshoring or reshoring critical components, and negotiated alternative commercial terms to preserve margins and maintain consistent availability to providers.

Clinically, these procurement responses can influence the mix of therapies offered: higher device or biologic costs may lead health systems and outpatient centers to re-evaluate formularies and standard operating procedures, favoring therapeutics with stronger cost-effectiveness evidence or lower logistic complexity. For home-care modalities and over-the-counter products, tariff-driven price pressures can affect retail pricing and patient out-of-pocket burdens, which in turn shape adherence to noninvasive regimens. Additionally, tariff-induced cost volatility encourages buyers to leverage longer-term contracting, group purchasing organizations, and strategic inventory buffering to mitigate disruption.

At a strategic level, renewed policy-driven cost pressures stimulate investment in domestic manufacturing capacity, increase interest in alternative materials and technologies that bypass tariffed inputs, and intensify collaboration between clinicians, supply chain managers, and procurement teams. While tariffs do not directly change clinical efficacy, their secondary effects on availability, pricing, and procurement behavior can alter the landscape in which therapeutic choices are made, emphasizing resilience, evidence-backed value, and strategic contracting as key mitigation levers.

Clear segmentation-driven insights into therapeutic modalities, product classes, anatomical applications, and care settings that explain adoption patterns and clinical workflows

A granular segmentation lens reveals important nuances in how treatments are applied, which stakeholders are most active, and where innovation is concentrated. When treatments are viewed through the prism of therapy modality, care ranges from home-based measures-such as ice therapy, rest and immobilization, and warm compress applications-through pharmacologic approaches that include both over-the-counter and prescription nonsteroidal anti-inflammatory drugs, to injectable therapies where corticosteroid injections remain a mainstay and emerging options include hyaluronic acid and platelet-rich plasma therapy. Physical therapy practices encompass cryotherapy, exercise therapy, and manual therapy, while surgical interventions are generally divided between arthroscopic and open surgical approaches. Each of these subsegments demonstrates distinct patterns: conservative home care and oral medication often serve as initial steps that prioritize accessibility and low cost, whereas injectable therapy and surgical intervention are typically pursued when symptoms persist or functional goals demand more aggressive management.

From a product-category perspective, antibiotics, biologics, corticosteroids, and nonsteroidal anti-inflammatory drugs play discrete roles with differing regulatory profiles, evidence requirements, and distribution pathways. Biologics and advanced regenerative products, for example, require distinct cold-chain logistics and clinical training for administration compared with small-molecule NSAIDs. Considering anatomical application sites, treatment selection is influenced by structural variation across the elbow, heel, hip, knee, and shoulder; site-specific biomechanical demands and patient activity levels drive clinical decision-making and rehabilitation planning. Finally, the end-user landscape spans ambulatory surgical centers, home care settings, hospitals, orthopedic clinics, and sports medicine centers, each with unique purchasing processes, clinical workflows, and volume profiles. Understanding how these segmentation axes interact is essential for tailoring clinical protocols, commercial strategies, and evidence-generation programs to real-world use cases.

Key regional distinctions in practice patterns, reimbursement realities, regulatory pathways, and supply chain factors that influence clinical adoption across major global markets

Regional dynamics materially influence how bursitis is diagnosed, treated, and reimbursed, with distinct patterns emerging across major geographies. In the Americas, care delivery often emphasizes rapid access to interventional procedures and well-established outpatient pathways; private payer mix and ambulatory surgical center growth shape the distribution of injectable therapies and arthroscopic procedures. Moving to Europe, Middle East & Africa, practice variation is greater due to heterogeneous reimbursement systems, regulatory regimes, and access to advanced biologics; in many markets, centralized procurement and national guideline alignment influence the uptake of higher-cost therapeutics, and public systems play an outsized role in defining standard of care. Across the Asia-Pacific region, demographic trends-such as rapidly aging populations in some countries and high sports participation in others-drive demand for both conservative and interventional approaches, while manufacturing hubs and regional supply chains influence availability and pricing dynamics.

Across all regions, the pace of digital adoption, tele-rehabilitation, and training for ultrasound-guided injections varies, affecting the extent to which remote care or image-guided interventions are integrated into routine practice. Moreover, regional regulatory pathways for novel biologics and cell-based therapies determine the speed with which evidence is translated into clinical availability. Trade policies and logistics infrastructure further modulate the reliability of product supply, and regional differences in clinical guideline development and specialist density shape where care is concentrated, whether that be in hospital systems, specialty clinics, or community-based settings.

Insightful analysis of competitive roles, strategic partnerships, and evidence-driven differentiation shaping the commercial landscape for bursitis therapeutics and services

Competitive dynamics within the bursitis treatment ecosystem reflect a heterogeneous mix of established pharmaceutical manufacturers, medical device companies, specialty biologics and regenerative medicine developers, digital health vendors, and service providers that support distribution and clinical training. Incumbent players continue to leverage scale, clinical relationships, and broad product portfolios to maintain access across hospitals and ambulatory centers, while smaller specialty firms focus on niche innovations-particularly in regenerative injections, point-of-care biologic processing, and novel delivery systems. At the same time, digital therapeutics and tele-rehabilitation suppliers are increasing their relevance by enabling long-term adherence to exercise therapy and facilitating remote clinician oversight.

Strategic behavior includes targeted partnerships between device or biologic developers and clinical networks to generate real-world evidence and to accelerate guideline adoption. Contract manufacturing organizations and logistics specialists also play a pivotal role, particularly for temperature-sensitive biologics and single-use procedural kits. Across the competitive landscape, differentiation increasingly depends on the strength and transparency of clinical evidence, the quality of training and clinician support programs, and the ability to demonstrate consistent outcomes in routine practice. Companies that can integrate evidence generation with pragmatic implementation support, while also addressing payer concerns regarding cost-effectiveness, are positioned to gain preferential access to procurement decision-makers and long-term contracts.

Practical and evidence-focused strategic recommendations for manufacturers, providers, and payers to enhance clinical value, supply resilience, and patient-centered outcomes

Industry leaders and clinical program directors should adopt a multi-pronged strategy to capture clinical value, improve patient outcomes, and mitigate commercial risk. First, prioritizing high-quality evidence generation for novel injectables and regenerative options is essential; randomized controlled trials complemented by pragmatic real-world studies will support payer engagement and guideline inclusion. Second, diversifying supply chains and exploring nearshoring options for critical components can reduce exposure to tariff volatility and shipping disruptions, while strategic contracting with group purchasers can stabilize pricing and availability. Third, investing in clinician education and structured implementation programs for ultrasound-guided injections and minimally invasive procedures will facilitate appropriate adoption and reduce variability in outcomes.

Additionally, integrating tele-rehabilitation and patient-facing adherence tools into care pathways can improve functional recovery rates and reduce downstream utilization of invasive procedures. Value-based contracting models that link reimbursement to patient-reported outcomes and functional benchmarks should be explored with payers to align incentives around meaningful recovery. Finally, companies and providers should develop clear, patient-centered communication frameworks to set expectations for recovery timelines, nonpharmacologic management, and the trade-offs between short-term symptom relief and longer-term tissue healing, thereby enhancing shared decision-making and adherence to conservative regimens when appropriate.

A rigorous mixed-methods research methodology combining expert interviews, clinical literature synthesis, supply chain analysis, and utilization data triangulation to ensure robust findings

The research underpinning these insights combined a layered methodology designed to triangulate clinical practice patterns, procurement behaviors, and innovation trends. Primary inputs included structured interviews with orthopedists, physiotherapists, interventional pain specialists, ambulatory surgery managers, and payer medical directors to capture frontline perspectives on treatment selection, barriers to adoption, and operational constraints. Secondary analysis drew upon peer-reviewed clinical literature, professional society guidelines, and regulatory filings to assess the comparative evidence base for pharmacologic, injectable, rehabilitative, and surgical approaches. Supply chain mapping and trade data reviews were used to understand sourcing vulnerabilities and the potential impacts of tariff shifts on component availability.

Wherever possible, qualitative findings were cross-checked with anonymized claims and utilization datasets to validate patterns of service delivery and care transitions. The methodology prioritized transparency about limitations: for example, national-level heterogeneity in coding practices can complicate cross-country comparisons, and emerging biologic technologies may lack long-term outcome data. Ethical safeguards included informed consent for interviews and de-identification of proprietary procurement information. Taken together, this mixed-methods approach offers a robust foundation for the insights presented while acknowledging areas where further prospective data collection would strengthen causal inference.

Concluding synthesis highlighting the intersection of clinical innovation, care delivery transformation, payer pressures, and supply resilience shaping future bursitis care

In summary, the management of bursitis is being reshaped by converging forces: therapeutic innovation in biologics and image-guided interventions; expanding capability for remote and home-based care; heightened payer emphasis on outcomes and cost-effectiveness; and supply chain pressures that influence product availability and pricing. These dynamics create both challenges and opportunities for stakeholders across the clinical and commercial spectrum. Clinicians are tasked with integrating new modalities while maintaining evidence-based pathways, manufacturers must demonstrate clear comparative value, and health systems need to design resilient procurement strategies that support consistent access to a full continuum of care.

Moving forward, the most successful programs will be those that align rigorous clinical evidence with pragmatic implementation supports, leverage digital tools to enhance recovery and adherence, and proactively manage supply risk through diversified sourcing and strategic contracting. By focusing on measurable functional outcomes and patient-centered care, stakeholders can improve recovery trajectories while ensuring sustainable delivery models that are responsive to evolving regulatory and commercial conditions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bursitis Treatment Market, by Treatment Type

  • 8.1. Home Care
    • 8.1.1. Ice Therapy
    • 8.1.2. Rest Immobilization
    • 8.1.3. Warm Compress
  • 8.2. Injectable Therapy
    • 8.2.1. Corticosteroid Injections
    • 8.2.2. Hyaluronic Acid Injections
    • 8.2.3. Platelet-Rich Plasma Therapy
  • 8.3. Oral Medication
    • 8.3.1. Over-The-Counter Nonsteroidal Anti-Inflammatory Drugs
    • 8.3.2. Prescription Nonsteroidal Anti-Inflammatory Drugs
  • 8.4. Physical Therapy
    • 8.4.1. Cryotherapy
    • 8.4.2. Exercise Therapy
    • 8.4.3. Manual Therapy
  • 8.5. Surgical Intervention
    • 8.5.1. Arthroscopic Surgery
    • 8.5.2. Open Surgery

9. Bursitis Treatment Market, by Product Category

  • 9.1. Antibiotics
  • 9.2. Biologics
  • 9.3. Corticosteroids
  • 9.4. Nonsteroidal Anti-Inflammatory Drugs

10. Bursitis Treatment Market, by Application Site

  • 10.1. Elbow
  • 10.2. Heel
  • 10.3. Hip
  • 10.4. Knee
  • 10.5. Shoulder

11. Bursitis Treatment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Orthopedic Clinics
  • 11.5. Sports Medicine Centers

12. Bursitis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bursitis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bursitis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bursitis Treatment Market

16. China Bursitis Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Arinna Lifesciences Ltd.
  • 17.8. AstraZeneca PLC
  • 17.9. Bioanalytical Systems, Inc.
  • 17.10. Bristol-Myers Squibb Company
  • 17.11. Crescent Formulations Pvt.Ltd.
  • 17.12. Eli Lilly and Company
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. GlaxoSmithKline plc
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. Merck & Co., Inc.
  • 17.17. NIDEK CO., LTD.
  • 17.18. Novartis AG
  • 17.19. Perrigo Company PLC
  • 17.20. Pfizer Inc.
  • 17.21. Sanofi S.A.
  • 17.22. Sun Pharmaceutical Industries Limited
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Topcon Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BURSITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BURSITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. G7 BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. NATO BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 246. NATO BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)